Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) have been assigned an average recommendation of “Hold” from the eleven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $24.14.

ITCI has been the subject of a number of analyst reports. Zacks Investment Research cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Leerink Swann restated an “outperform” rating on shares of Intra-Cellular Therapies in a research note on Monday, March 20th. Piper Jaffray Companies cut Intra-Cellular Therapies from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $22.00 to $10.00 in a research note on Monday, May 1st. Ladenburg Thalmann Financial Services cut Intra-Cellular Therapies from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 2nd. Finally, Cantor Fitzgerald set a $29.00 price objective on Intra-Cellular Therapies and gave the stock a “buy” rating in a research note on Thursday, May 11th.

A number of large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $574,000. State Street Corp boosted its stake in Intra-Cellular Therapies by 18.0% in the fourth quarter. State Street Corp now owns 972,868 shares of the biopharmaceutical company’s stock worth $14,686,000 after buying an additional 148,745 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $644,000. Keybank National Association OH acquired a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $303,000. Finally, Royce & Associates LP boosted its stake in Intra-Cellular Therapies by 289.6% in the fourth quarter. Royce & Associates LP now owns 30,000 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 22,300 shares during the period. Institutional investors own 68.55% of the company’s stock.

Intra-Cellular Therapies (NASDAQ ITCI) traded up 3.26% during trading on Tuesday, hitting $10.13. The stock had a trading volume of 472,754 shares. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $45.20. The stock’s 50-day moving average is $10.54 and its 200-day moving average is $13.54. The stock’s market capitalization is $439.84 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.12. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.02 million. Intra-Cellular Therapies had a negative return on equity of 29.74% and a negative net margin of 27,180.94%. During the same period in the prior year, the business posted ($0.64) EPS. On average, analysts predict that Intra-Cellular Therapies will post ($3.03) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Receives Consensus Recommendation of “Hold” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/13/intra-cellular-therapies-inc-itci-receives-consensus-recommendation-of-hold-from-analysts.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.